Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A single infusion of zimislecel, an islet cell therapy by Vertex Pharmaceuticals, dramatically reduced diabetes distress and fear of hypoglycemia in adults with type 1 diabetes over one year. All 12 trial participants achieved HbA1c below 7%, and 83% no longer needed insulin. The findings suggest this therapy goes beyond blood sugar control to meaningfully improve patients' quality of life.
A single infusion could change everything for people living with type 1 diabetes. New data from the FORWARD-VX-880-101 trial show that zimislecel (Vertex Pharmaceuticals), a stem cell-derived islet cell therapy, not only restored glucose regulation but also significantly reduced the emotional and psychological burden of living with the disease — including diabetes distress and fear of hypoglycemia — over a full year of follow-up.
The trial enrolled 12 adults with type 1 diabetes who had impaired hypoglycemia awareness and a history of severe hypoglycemic episodes. After a single infusion, all participants achieved HbA1c levels below 7%, no severe hypoglycemia occurred, and 83% were able to stop using exogenous insulin entirely. Patient-reported scores for both diabetes distress and hypoglycemia fear declined steadily throughout the year.
By the Numbers:
Why it matters: Beyond the biochemical wins, this therapy addresses the daily psychological toll of managing type 1 diabetes — the constant worry, vigilance, and fear that accompany the disease. Researchers note that ongoing immunosuppression (required post-infusion) may still contribute to some residual distress, pointing to a key area for future refinement.
